A case of ICIs-associated arthritis caused by Toripalimab initially presenting as oedema in both lower limbs [0.03%]
特瑞普利单抗引起的关节炎1例首发双下肢水肿
Jie-Ling Zhang,Hao Yang,Zhi-Li Zhou et al.
Jie-Ling Zhang et al.
The use of immune checkpoint inhibitors (ICIs) has offered new hope for patients with malignant tumours; however, it is essential to acknowledge their potential toxic side effects. Among these, ICIs-associated arthritis (IA) is not uncommon...
Postmarket review of photosensitivity associated with select BRAF and MEK inhibitors [0.03%]
针对部分BRAF和MEK抑制剂光敏反应的市面回顾分析
Nicholas Chow,Melissa Reyes,Afrouz Nayernama et al.
Nicholas Chow et al.
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are approved in the U.S. to be given in combination or as single agents to treat patients with BRAF V600E/K-positive solid and histiocytic neoplasms. During postmarketing safety surveillance...
Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation [0.03%]
达雷妥尤单抗为基础的早期治疗在复发和难治性多发性骨髓瘤患者中表现出显著疗效：一项真实世界回顾性研究
Yi Chen,Qinyun Cai,Zongjian Qiu et al.
Yi Chen et al.
This research aimed to assess the effectiveness of daratumumab in the treatment of relapsed and refractory multiple myeloma (RRMM) within a real - world setting. We conducted a retrospective analysis of the clinical features and treatment o...
Unilateral facial nerve paralysis following prolonged weekly paclitaxel therapy: a rare case of cranial neurotoxicity with diagnostic challenges [0.03%]
长期每周接受紫杉醇治疗后出现面神经麻痹的一个罕见颅神经毒性的病例报告及诊断挑战
Ergin Aydemir,Alper Türkel,Kübra Okur et al.
Ergin Aydemir et al.
Background: Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer. While peripheral neuropathy is a well-recognized dose-limiting toxicity of paclitaxel, cranial nerve involvement remains e...
Clinical evaluation of camrelizumab combined with transarterial chemoembolization in the interventional therapy of hepatocellular carcinoma with liver cirrhosis [0.03%]
卡瑞利珠单抗联合肝动脉化疗栓塞治疗肝硬化肝细胞癌的临床评价
Jian Chen,Mengshan Huang
Jian Chen
This retrospective study evaluated the clinical efficacy of camrelizumab combined with transarterial chemoembolization (TACE) in 120 hepatocellular carcinoma (HCC) patients with liver cirrhosis. Based on the intervention received, patients ...
Targeting leukemic stem cells: enhanced eradication via tivantinib (ARQ197) and asciminib (ABL001) with molecular docking-guided screening of therapeutic derivatives [0.03%]
靶向白血病干细胞：通过分子对接引导的筛选，使用tivantinib（ARQ197）和asciminib（ABL001）及其治疗衍生物进行增强清除
İlknur Karatekin Arik,Nurcan Gümüş,İlayda Alcitepe et al.
İlknur Karatekin Arik et al.
This study is the first to investigate the therapeutic potential of a mono/combination treatment with the selective phase III BCR::ABL1 tyrosine kinase inhibitor (TKI) asciminib (ABL001) and the c-MET inhibitor tivantinib (ARQ197) in hemato...
Comparison of the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a retrospective study [0.03%]
呋喹替尼单药与联合免疫检查点抑制剂治疗晚期结直肠癌的疗效比较：回顾性研究
Li Huang,Hui Rao,Chunmei Wu et al.
Li Huang et al.
This study explored the efficacy of fruquintinib monotherapy versus fruquintinib combined with immune checkpoint inhibitors in the treatment of advanced proficient mismatch repair/microsatellite stable-type colorectal cancer. We retrospecti...
Determination of survival associated genetic biomarkers to discover novel therapeutic targets for acute myeloid leukaemia [0.03%]
用于发现急性髓系白血病新治疗靶点的与生存相关遗传生物标志物的鉴定
Cansu Ergun,Yağmur Kiraz,Gizem Ayna Duran
Cansu Ergun
Acute myeloid leukemia (AML) is a heterogeneous malignancy specified by clonal proliferation of hematopoietic stem cells. This study identifies novel therapeutics for AML by integrating differential gene expression (DEG) and survival analys...
Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway [0.03%]
CHD阻滞非小细胞肺癌的进展通过抑制METTL3/EPHA7通路
Teng Ren,Hongpei Zhang,Yurou Liu et al.
Teng Ren et al.
Chidamide, a histone deacetylase inhibitor with established anti-tumor properties, requires further investigation regarding its specific impact on lung cancer progression. Our results showed that chidamide treatment significantly inhibited ...
Impact of response on survival according to type of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer [0.03%]
免疫检查点抑制剂的类型和疗效对晚期非小细胞肺癌患者生存率的影响
Tetsuo Shimizu,Masayuki Nomoto,Yoshiko Nakagawa et al.
Tetsuo Shimizu et al.
Response is a surrogate marker of survival used to determine the efficacy of cancer chemotherapy. However, it is unclear whether the impact of the response on survival depends on the ICI type. This study aimed to assess whether the impact o...